Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
D. W. Siemann, D. J. Chaplin & M. R. Horsman. (2017) Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and Anti-Angiogenic Agents to Treat Cancer. Cancer Investigation 35:8, pages 519-534.
Read now
Read now
Lotte B. Bertelsen, Yuan Yuan Shen, Thomas Nielsen, Hans Stødkilde-Jørgensen, G. Kenneth Lloyd, Dietmar W. Siemann & Michael R. Horsman. (2011) Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. International Journal of Radiation Biology 87:11, pages 1126-1134.
Read now
Read now
Erik Larsson, Michael Ljungberg, Sven-Erik Strand & Bo-Anders Jönsson. (2011) Monte Carlo calculations of absorbed doses in tumours using a modified MOBY mouse phantom for pre-clinical dosimetry studies. Acta Oncologica 50:6, pages 973-980.
Read now
Read now
Cai Grau, Dag Rune Olsen, Jens Overgaard, Morten Høyer, Jacob Christian Lindegaard & Ludvig Paul Muren. (2010) Biology-guided adaptive radiation therapy – presence or future?. Acta Oncologica 49:7, pages 884-887.
Read now
Read now
Articles from other publishers (16)
Hooman Salavati, Pim Pullens, Charlotte Debbaut & Wim Ceelen. (2023) Hydraulic conductivity of human cancer tissue: A hybrid study. Bioengineering & Translational Medicine.
Crossref
Crossref
Hooman Salavati, Pim Pullens, Wim Ceelen & Charlotte Debbaut. (2023) Drug transport modeling in solid tumors: A computational exploration of spatial heterogeneity of biophysical properties. Computers in Biology and Medicine 163, pages 107190.
Crossref
Crossref
Toby Holmes, Andrew W. Brown, Marie Suggitt, Lucy A. Shaw, Lucy Simpson, Joseph P. A. Harrity, Gillian M. Tozer & Chryso Kanthou. (2020) The influence of hypoxia and energy depletion on the response of endothelial cells to the vascular disrupting agent combretastatin A-4-phosphate. Scientific Reports 10:1.
Crossref
Crossref
Yewei Liu, Shuncong Wang, Xiaohui Zhao, Yuanbo Feng, Guy Bormans, Johan Swinnen, Raymond Oyen, Gang Huang, Yicheng Ni & Yue Li. (2020) Predicting Clinical Efficacy of Vascular Disrupting Agents in Rodent Models of Primary and Secondary Liver Cancers: An Overview with Imaging-Histopathology Correlation. Diagnostics 10:2, pages 78.
Crossref
Crossref
Yewei Liu, Ting Yin, Frederik De Keyzer, Yuanbo Feng, Feng Chen, Jianjun Liu, Shaoli Song, Jie Yu, Vincent Vandecaveye, Johan Swinnen, Guy Bormans, Uwe Himmelreich, Raymond Oyen, Jian Zhang, Gang Huang & Yicheng Ni. (2017) Micro-HCCs in rats with liver cirrhosis: paradoxical targeting effects with vascular disrupting agent CA4P. Oncotarget 8:33, pages 55204-55215.
Crossref
Crossref
Anne-Catherine Fruytier, Cecile S. Le Duff, Chrystelle Po, Julie Magat, Caroline Bouzin, Marie-Aline Neveu, Olivier Feron, Benedicte F. Jordan & Bernard Gallez. (2016) The Blood Flow Shutdown Induced by Combretastatin A4 Impairs Gemcitabine Delivery in a Mouse Hepatocarcinoma. Frontiers in Pharmacology 7.
Crossref
Crossref
Meng Gao, Dongjian Zhang, Qiaomei Jin, Cuihua Jiang, Cong Wang, Jindian Li, Fei Peng, Dejian Huang, Jian Zhang & Shaoli Song. (2016) Combretastatin-A4 phosphate improves the distribution and antitumor efficacy of albumin-bound paclitaxel in W256 breast carcinoma model. Oncotarget 7:36, pages 58133-58141.
Crossref
Crossref
Florence Colliez, Anne‐Catherine Fruytier, Julie Magat, Marie‐Aline Neveu, Patrice D. Cani, Bernard Gallez & Bénédicte F. Jordan. (2015) Monitoring Combretastatin A4–induced tumor hypoxia and hemodynamic changes using endogenous MR contrast and DCE‐MRI. Magnetic Resonance in Medicine 75:2, pages 866-872.
Crossref
Crossref
Dietmar W. Siemann & Michael R. Horsman. (2015) Modulation of the tumor vasculature and oxygenation to improve therapy. Pharmacology & Therapeutics 153, pages 107-124.
Crossref
Crossref
Mostafa Sefidgar, M Soltani, Kaamran Raahemifar, Hossein Bazmara, Seyed Mojtaba Mousavi Nayinian & Majid Bazargan. (2014) Effect of tumor shape, size, and tissue transport properties on drug delivery to solid tumors. Journal of Biological Engineering 8:1.
Crossref
Crossref
A.-C. Fruytier, J. Magat, M.-A. Neveu, O. Karroum, C. Bouzin, O. Feron, B. Jordan, G. O. Cron & B. Gallez. (2014) Dynamic contrast-enhanced MRI in mouse tumors at 11.7 T: comparison of three contrast agents with different molecular weights to assess the early effects of combretastatin A4. NMR in Biomedicine 27:11, pages 1403-1412.
Crossref
Crossref
RUI-MENG YANG, YONG ZOU, DAN-PING HUANG, SHENG-SHENG LAI, XIANG-DONG XU, XIN-HUA WEI, HAN-ZHENG CHANG, TONG-KUN HUANG, LI WANG, WEN-JIE TANG & XIN-QING JIANG. (2014) In vivo assessment of the vascular disrupting effect of M410 by DCE-MRI biomarker in a rabbit model of liver tumor. Oncology Reports 32:2, pages 709-715.
Crossref
Crossref
Michael R. Horsman, Morten Busk, Thomas Nielsen, Marianne Nordsmark & Jens Overgaard. 2014. Hypoxia and Cancer. Hypoxia and Cancer
179
201
.
Thomas Nielsen, Thomas Wittenborn & Michael Horsman. (2012) Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) in Preclinical Studies of Antivascular Treatments. Pharmaceutics 4:4, pages 563-589.
Crossref
Crossref
Gregory L. Pishko, Garrett W. Astary, Jingya Zhang, Thomas H. Mareci & Malisa Sarntinoranont. (2012) Role of convection and diffusion on DCE-MRI parameters in low leakiness KHT sarcomas. Microvascular Research 84:3, pages 306-313.
Crossref
Crossref
Yanchun Wei, Qun Chen, Baoyan Wu, Aiguo Zhou & Da Xing. (2012) High-sensitivity in vivo imaging for tumors using a spectral up-conversion nanoparticle NaYF4: Yb3+, Er3+ in cooperation with a microtubulin inhibitor. Nanoscale 4:13, pages 3901.
Crossref
Crossref